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Bcell antigen receptor (BCR) engagement can lead tomany different physiologic outcomes.
To achieve an appropriate response, the BCR signal is interpreted in the context of other
stimuli and several additional receptors on the B cell surface participate in the modulation
of the signal. Two members of the Siglec (sialic acid-binding immunoglobulin-like lectin)
family, CD22 and Siglec-G have been shown to inhibit the BCR signal. Recent ﬁndings indi-
cate that the ability of these two receptors to bind sialic acids might be important to induce
tolerance to self-antigens. Sialylated glycans are usually absent on microbes but abundant
in higher vertebrates and might therefore provide an important tolerogenic signal. Since
the expression of the speciﬁc ligands for Siglec-G and CD22 is tightly regulated and since
Siglecs are not only able to bind their ligands in trans but also on the same cell surface this
might provide additional mechanisms to control the BCR signal. Although both Siglec-G
and CD22 are expressed on B cells and are able to inhibit BCR mediated signaling, they
also show unique biological functions. While CD22 is the dominant regulator of calcium
signaling on conventional B2 cells and also seems to play a role on marginal zone B cells,
Siglec-G exerts its function mainly on B1 cells and inﬂuences their lifespan and antibody
production. Both Siglec-G and CD22 have also recently been linked to toll-like receptor sig-
naling and may provide a link in the regulation of the adaptive and innate immune response
of B cells.
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INTRODUCTION TO THE SIGLEC FAMILY
B cells are an important part of the immune system and through
production of antibodies crucially contribute to the humoral
immune response. Recognition of antigen by the B cell antigen
receptor (BCR) is the main event in the B cell immune response
and signaling through the BCR complex is tightly regulated by sev-
eral different co-receptors. CD22 and Siglec-G are twomembers of
the Siglec (sialic acid-binding immunoglobulin-like lectins) fam-
ily and have been shown to negatively regulate B cell signaling.
The review focuses on the role of CD22 and Siglec-G in B cells and
discusses their possible biological functions.
Siglecs are a family of sialic acid-binding proteins expressed on
cells of the immune system (Crocker et al., 2007) with the excep-
tion of myelin associated glycoprotein (MAG) which is expressed
on myelinating glia cells, suggesting a role in the nervous system
(Quarles, 2007). Also, few other human Siglecs have been detected
on other tissues in addition to cells of the immune system. The
expression of Siglec-6 has been observed on B cells and placental
trophoblasts (Patel et al., 1999; Brinkman-Van der Linden et al.,
2007) and Siglec-11 can be detected on macrophages and brain
microglia (Angata et al., 2002). However, the majority of Siglecs
seems to play a role mainly in the immune system in both human
and mouse. Some Siglecs show a very restricted expression pattern
(Table 1). CD22 and Sialoadhesin have been found only on B cells
or macrophages (Crocker et al., 1994, 2007), respectively. Other
Siglecs are expressed more broadly. For example, Siglec-9 can be
found onB cells, neutrophils,monocytes, and a fraction of NK and
T cells (Zhang et al., 2000).Murine Siglec-G ismainly expressed on
B cells, however it might be also expressed on other cell types such
as dendritic cells (Ding et al., 2007). The humanortholog Siglec-10
has been detected on B cells, NK cells, monocytes, dendritic cells,
and eosinophils (Munday et al., 2001).
Members of the Siglec family are expressed in different ver-
tebrates and are present in all investigated mammalian species
(Angata, 2006). However, only four members of the Siglec family-
Sialoadhesin (Siglec-1), CD22 (Siglec-2), MAG, and Siglec-15 are
highly conserved throughout mammalian evolution. In contrast,
the group of CD33 related Siglecs is rapidly evolving and often
no clear orthologs can be assigned between different mammalian
species (Angata et al., 2004). Humans express a larger set of CD33
related Siglecs (CD33/Siglec-3, Siglec-4, -5, -6, -7, -8, -9, -10, -
11, -14, -16) than mice (CD33/Siglec-3, Siglec-E, -F, -G, -H) and
the distribution on different cell types seems to be unique for
each species as well. Interestingly Siglec-G is one of the few CD33
related Siglecs with a clear human ortholog – Siglec-10. In addi-
tion to sequence homology, both Siglec-G and Siglec-10 can be
detected on B cells suggesting that they might also share some
functional similarity (Munday et al., 2001).
All Siglecs share some structural features. They are transmem-
brane proteins with a variable number of immunoglobulin-like
domains in their extracellular portions and a cytoplasmic part
at the carboxy terminus. Located within the cytoplasmic tail are
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Table 1 | Expression pattern of murine and human Siglecs on the cells of the immune system.
B cells T cells NK cells Monocytes Macrophages Dendritic cells Neutrophils Eosinophils Basophils
Human CD22 Siglec-7 (sub) Siglec-7 CD33 Sialoadhesin CD33 Siglec-5 Siglec-8 Siglec-5
Siglec-5 Siglec-9 Siglec-9 Siglec-5 CD33 (sub) Siglec-7 Siglec-9 Siglec-10 Siglec-8
Siglec-6 Siglec-10 Siglec-7 Siglec-5 Siglec-9 (sub) Siglec-14
Siglec-9 Siglec-9 Siglec-11 Siglec-10
Siglec-10 Siglec-10 Siglec-15 Siglec-15
Siglec-14 Siglec-16
Mouse CD22 Siglec-E (sub) Siglec-E Sialoadhesin Siglec-E CD33 Siglec-F
Siglec-G Siglec-F (sub) Siglec-H (sub) Siglec-E
The table summarizes the expression of murine and human Siglecs on different cell types of the immune system. Differences in expression levels or the frequency
of Siglec expressing cells in a given population are not depicted. CD22 is also known as Siglec-2, CD33 as Siglec-3, Sialoadhesin as Siglec-1. Sub, subpopulations (Li
et al., 2001; Zhang et al., 2004; Varki and Angata, 2006; Angata et al., 2007; Cao and Crocker, 2010).
sites for possible tyrosine phosphorylation. These tyrosines are
often part of the consensus sequence of immunoreceptor tyrosine
based inhibitorymotifs (ITIMs).After phosphorylation, ITIMs are
able to recruit Src homology 2 (SH2) domain containing signal-
ing molecules such as the tyrosine phosphatases SHP-1 or SHP-2.
Interaction with SHP-1 could be demonstrated for CD22 (Doody
et al., 1995), Siglec-7, Siglec-9 (Ikehara et al., 2004), and Siglec-10
(Whitney et al., 2001). ITIMs are sequence motifs present in many
well-characterized inhibitory receptors such as CD72, PIR-B, or
FcγRIIB (Nitschke et al., 1997) and therefore ITIM containing
Siglecs are expected to play an inhibitory role in cell signaling.
Indeed, several Siglecs have been reported to inhibit different
signaling pathways. Siglec-7 and -9 can inhibit TCR mediated sig-
naling (Ikehara et al., 2004), Siglec-G and CD22 are inhibitors
of the BCR signal (Nitschke et al., 1997; Hoffmann et al., 2007),
Siglec-E probably plays an inhibitory role in Toll-like receptor
(TLR)-mediated IFNβ production (Boyd et al., 2009). However,
some Siglecs lack ITIM motifs, associate with activating recep-
tors and are therefore thought to be activatory transmembrane
proteins (Crocker et al., 2007).
Unlike most other proteins from the immunoglobulin super-
family, Siglecs do not bind protein determinants but recognize
exclusively sialylated carbohydrates. Sialylation is a commonmod-
iﬁcation of glycoproteins in vertebrates and higher invertebrates,
but relatively rare outside the Deuterostomia lineage (Angata and
Varki, 2002). Sialic acids are a family of 9-carbon monosaccharides
derived fromneuraminic acid.These sugars are frequently foundat
the terminal position of oligosaccharide chains attached to numer-
ous proteins creating a broad array of possible Siglec ligands. The
substrate speciﬁcity of different Siglecs is very diverse and binding
afﬁnity can be inﬂuenced by the type of the sialic acid, the type of
linkage to the underlying oligosaccharide chain and also the pres-
ence of other proximal sugars (Angata, 2006). Some Siglecs show
strict ligand requirements and some recognize a broader range
of sialic acids. Given the complex expression pattern of Siglecs
on different cells of the immune system, the plasticity of possible
interactions and the prominence of sialic acids on cell surfaces, it is
not surprising that Siglecs are believed to participate in many dif-
ferent biological processes. Different members of the Siglec family
have been suggested to play a role in cell–cell adhesion (Schadee-
Eestermans et al., 2000), regulation of responses to tissue damage
(Chen et al., 2009), controlling allergic reactions of eosinophils
(Zhang et al., 2007), and maintenance of tolerance (Duong et al.,
2010). Yet, because of the complexity of Siglec biology and due to
recent discoveries of new Siglecs the exact biological function of
many Siglecs remains incompletely understood.
INHIBITION OF BCR SIGNALING BY Siglec-G AND CD22
Siglec-G and CD22 are the only two Siglecs reported to be
expressed on murine B cells so far. While CD22 appears to be
expressed exclusively on B cells, Siglec-G is expressed predomi-
nantly on B cells, but is possibly also present on dendritic cells and
on other cell types as well (Ding et al., 2007). Both Siglecs seem
to be able to associate with the BCR (Peaker and Neuberger, 1993;
Zhang andVarki, 2004 andour unpublished observation) andneg-
atively regulate BCR mediated signaling. Siglec-G has been shown
to be an important inhibitor on B1a cells, since Siglec-G-deﬁcient
B1a cells show increased calcium signaling after anti-IgM stim-
ulation (Hoffmann et al., 2007). Siglec-G is also able to dampen
the BCR signal when transfected into DT40 cells, a B cell line
lacking endogenous Siglecs and widely used to study compo-
nents of the BCR signaling cascade. However, conventional B2
cells show normal calcium signaling in Siglec-G-deﬁcient mice,
indicating a redundant function of Siglec-G in this B cell popu-
lation (Hoffmann et al., 2007). The dominant inhibitor in con-
ventional (B2) cells seems to be CD22 and CD22-deﬁcient mice
show increased calcium signaling in these cells. While the exact
biochemical mechanism for the inhibition mediated by Siglec-G
is mostly unknown, comprehensive studies have clariﬁed signaling
pathways downstream of CD22.
CD22 contains six tyrosines in its cytoplasmic tail, three of
which are found within conventional ITIMs (Y783, Y843, Y863),
one is part of an ITIM-like motif (Y817), and one is needed for
the recruitment of Grb2 (Y828; Otipoby et al., 2001). CD22 is
rapidly phosphorylated after BCR crosslinking and docking sites
for different signaling molecules are created. The Src kinase Lyn
plays a central role in this process (Smith et al., 1998). B cells from
Lyn-deﬁcient mice fail to induce CD22 phosphorylation after BCR
stimulation and as a consequence SHP-1 recruitment to CD22 is
abolished. SHP-1 is a phosphatase also involved in negative signal-
ing from other receptors and believed to be the central signaling
molecule mediating CD22 inhibition. CD22 is unable to inhibit
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BCR signaling in DT40 cells lacking SHP-1, but does not seem to
require SHIP for its inhibitory function (Chen et al., 2004). The
role of Grb2 binding to the tail of CD22 is not known. However,
Grb2−/− mice show enhanced Ca2+ responses of their splenic
B cells, similar to CD22−/− mice and decreased CD22 phospho-
rylation, suggesting a CD22-dependent mechanism (Ackermann
et al., 2011; Jang et al., 2011).
The increase of free cytosolic calcium in B cells after BCR stim-
ulation is the product of two processes. First, the BCR signaling
cascade leads to the phosphorylation and activation of differ-
ent signaling molecules such as Btk, BLNK/SLP65, and PLCγ2.
PLCγ2 mediates the production of inositol-1,4,5-trisphosphate
(IP3). This signaling molecule binds to IP3 receptor channels on
the endoplasmic reticulum and initiates the release of calcium
from intracellular calcium stores into the cytosol (Figure 1). The
second mechanism contributing to the elevation of intracellular
calcium levels is the regulation of calcium transport across the
plasmamembrane.Activation of calcium release activated calcium
(CRAC) channels allows extracellular calcium to enter the cyto-
plasm. This process can be antagonized by calcium ATPase pumps
(PMCA; Scharenberg et al., 2007). CD22 seems to affect both, the
early events leading to the release of calcium and also the late
events affecting the duration of the calcium signal. The phospho-
rylation of proteins involved in the calcium cascade such as CD19
(Fujimoto et al., 1999) and BLNK/SLP65 (Gerlach et al., 2003) is
increased in B cells from CD22-deﬁcient mice after anti-IgM stim-
ulation. Furthermore, CD22 has been shown to interact with the
calcium pump PMCA4 resulting in the activation of PMCA4 and
augmented calcium efﬂux. This interaction is dependent on acti-
vation induced CD22 phosphorylation and recruitment of SHP-1
(Figure 1; Chen et al., 2004).
It has been convincingly shown that CD22 can inhibit BCR
mediated signaling if the BCR is of the IgM isotype. During an
immune response B cells are induced to switch to express IgG
BCRs. Signals transmitted through the IgG BCR seem to differ
from those mediated by IgM and the different signaling prop-
erties have been attributed to the differences in the cytoplasmic
tail. BCRs with an IgG tail segment have been shown to induce
stronger calcium signal than IgM BCRs (Horikawa et al., 2007).
After initial reports that CD22 phosphorylation is impaired in
IgG-expressing B cell lines (Wakabayashi et al., 2002), it has been
assumed that CD22 is unable to regulate IgG transmitted signals.
However, in vivo studies have challenged this model (Horikawa
et al., 2007; Waisman et al., 2007). Knock-in mice expressing only
membrane IgG1 show a strong calcium signal, yet the signal can
be further increased if CD22 is absent. Furthermore, CD22 phos-
phorylation and association with SHP-1 after BCR stimulation
are normal. This indicates that CD22 might also play a role in IgG
mediated signaling (Waisman et al., 2007).
Although it has been well established that CD22 functions
mainly as a negative regulator, further complexity arises by the
ability of CD22 to associate with other signaling molecules oth-
erwise involved in positive BCR signaling. Among others, PLCγ2,
Syk, and PI3K have been reported to be recruited to CD22 (Law
et al., 1996; Yohannan et al., 1999). However, the biological role of
these interactions remains unclear.
Siglec-G is a recently discovered protein and therefore the exact
biochemical function of this protein in B cells is not well deﬁned.
The phosphorylation of several signaling molecules involved in
BCR mediated signaling such as PLCγ, Btk, and BLNK is normal
in Siglec-G-deﬁcient B cells (Hoffmann et al., 2007). However,
Siglec-G-deﬁcient B1a cells have been shown to contain increased
levels of the transcription factor NFATc1 (Jellusova et al., 2010a).
NFATc1 is known to be activated by the phosphatase calcineurin
in a calcium dependent manner. The expression of the short iso-
form NFATc1/A can be promoted in an autoregulatory manner
FIGURE 1 | Regulation of BCR signaling by CD22 and Siglec-G. CD22
regulates BCR signaling in conventional B2 cells. After antigen stimulation,
CD22 is tyrosine-phosphorylated by Lyn and docking sites for SH2 domain
containing proteins are created. CD22 has six tyrosines in its intracellular tail,
of which three form ITIM motifs (shown as green boxes). SHP-1 binds to two
phosphorylated ITIMs. SHP-1 interferes with signaling pathways leading to the
depletion of calcium stores from the endoplasmic reticulum (ER) and
promotes calcium efﬂux through PMCA4. Shc and Grb2 bind to the indicated
tyrosines and form a complex with SHIP. However the role of these molecules
in CD22 transmitted inhibitory signals is not known. Siglec-G also has one ITIM
motif (green box) and dampens the calcium signal on B1 cells thereby possibly
inﬂuencing the activity and expression levels of the transcription factor NFATc1.
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due to a NFAT binding site in the P1 promoter (Chuvpilo et al.,
2002). Therefore, increased calcium signals in Siglec-G-deﬁcient
B1a cells could lead to increased expression of NFATc1 (Figure 1).
Siglec-G has also been proposed to regulate activation of the NFκB
pathway in B1 cells (Ding et al., 2007). However, samples used in
the study of Ding et al. (2007) were prepared from total peritoneal
washouts and likely contained other cells apart from B1 cells. Since
the frequency of B1 cells in the lymphocyte population is signiﬁ-
cantly higher in the peritoneal cavity from Siglec-G-deﬁcient mice
than in wild type mice, the results from these experiments might
be misleading. Enhanced NFκB activation in Siglec-G-deﬁcient B1
cells could not be conﬁrmed in our experiments with puriﬁed B1
cells (Jellusova et al., 2010a).
SIGLECS AND TLR SIGNALING
So far most studies have focused on the role of Siglec-G and CD22
in regulation of BCR-mediated signaling. However, recent evi-
dence suggests that both Siglecs may play a role in TLR signaling
as well. TLRs recognize speciﬁc bacterial or viral products such as
dsRNA (TLR3), LPS (TLR4), dsDNA (TLR9), ssRNA (TLR7), or
Flagellin (TLR5). TLR2 is able to bind a wide range of microbial
structures including peptidoglycan and lipoteichoic acid. TLR1
and TLR6 can form heterodimers with TLR2 and discriminate
between triacyl- and diacyl-lipopeptides (Akira andTakeda, 2004).
TLRs are expressed by cells of the innate immune system such
as dendritic cells and monocytes, but are also present on B cells.
Siglec-G-deﬁcient B cells show increased proliferation after stimu-
lationwith LPS (TLR4 ligand),R848 (TLR7 ligand),orCpG (TLR9
ligand; Jellusova et al., 2010b). Also CD22-deﬁcient B cells exhibit
hyperproliferation when stimulated with these ligands as well as
after stimulationwith polyI:C (TLR3 ligand; Jellusova et al., 2010b;
Kawasaki et al., 2011). The expression levels of TLR3, TLR4, and
TLR9 on CD22-deﬁcient cells do not exceed the levels in wild type
cells and the sequestration of CD22 by immobilized anti-CD22
antibodies results in enhanced proliferation after TLR stimula-
tion, indicating that CD22 might affect downstream events in TLR
signaling (Kawasaki et al., 2011; Figure 2). Ectopic expression of
CD22 in a TLR4 reporter cell line, was found to dampen NFκB
transcriptional activity (Kawasaki et al., 2011). How Siglec-G and
CD22 interfere with TLR-transmitted signals is not known. How-
ever, TLR induced expression of SOCS1 and SOCS3 is reduced
in CD22-deﬁcient B cells (Kawasaki et al., 2011). SOCS1 and
SOCS3 are known to play a negative role in cytokine and TLR-
mediated signaling (Naka et al., 2005) and reduced expression of
these molecules might result in a prolonged TLR signal.
It is interesting to note, that unlike TLR4, TLR7, and TLR9 are
not expressed on the cell surface, but are instead localized to the
endosomes. CD22 is known to constantly recycle between the cell
surface and the endosomes und can therefore possibly colocalize
with the TLRs (Figure 2). It would be interesting to study whether
the proximity to the TLRs is necessary for Siglec-G and CD22 to
inhibit TLR-mediated proliferation or whether the inhibition is
mediated in a more indirect manner. Other Siglecs have also been
shown to inhibit TLR-mediated signaling (Blasius and Colonna,
2006; Boyd et al., 2009) suggesting that the ability to modulate
TLR signals might be a function shared by the whole Siglec family.
Siglec-E has been shown to recruit SHP-1 and SHP-2 after LPS
FIGURE 2 | Siglecs andTLRs. Siglec-G and CD22-deficient B cells show
increased proliferation afterTLR stimulation. First evidence suggests
that CD22 might be able to regulate NFκB activity after TLR stimulation.
CD22 can be internalized by endocytosis and may be in direct contact to
TLRs found in endosomes.Whether Siglec-G can limit TLR signaling via
modulating NFκB activity in B cells is not known.
stimulation and to inhibit TLR-mediated NFκB activation and
cytokine production (Boyd et al., 2009).
The possible involvement of Siglec-G and CD22 in TLR signal-
ing is interesting in several ways. Stimulation of B cells with TLR
ligands can lead to proliferation, upregulation of the plasma cell
marker Syndecan-1 and antibody secretion in vitro. Since TLRs are
germline encoded and the presence of the corresponding ligand
will activate all B cells irrespective of their BCR speciﬁcity, TLR
signaling has been suggested to represent an innate-like immune
response in B cells. This aspect of B cell biology has attracted less
attention so far than BCR mediated signaling and how TLR signals
aremodulated on B cells is incompletely understood. Furthermore
a combined BCR and TLR signal can lead to the activation of some
auto-reactive B cells (Viglianti et al., 2003; Lau et al., 2005) and
enhanced TLR signaling can lead to the development of autoim-
munity (Deane et al., 2007). Therefore a better understanding of
TLR signals on B cells could be relevant to better understand how
tolerance can be broken. Siglec-G and CD22 could provide a link
between the adaptive and innate immune responses of B cells and
it would be interesting to study how BCR- and TLR-transmitted
signals can inﬂuence each other.
B CELL DEVELOPMENT AND DIFFERENTIATION IN Siglec-G
AND CD22-DEFICIENT MICE
Although both Siglec-G and CD22 are expressed from the pre B
cell stage onward, neither seems to play a vital role in B cell devel-
opment in the bone marrow since no defects have been observed
in Siglec-G or CD22-deﬁcient mice (Otipoby et al., 1996; O’Keefe
et al., 1996; Sato et al., 1996; Nitschke et al., 1997; Hoffmann et al.,
2007). Mature B cells are present in normal numbers in CD22-
deﬁcient mice but show an increased apoptosis rate after anti-IgM
stimulation in vitro and a shortened lifespan in vivo. Decreased
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survival after anti-IgM stimulation, however does not reﬂect an
altered immune response, since CD22-deﬁcient mice show a nor-
mal production of antigen speciﬁc antibodies after immunization
with thymus-dependent antigen (Otipoby et al., 1996; Sato et al.,
1996; Nitschke et al., 1997). This is probably due to other signals
that can rescue survival of activated CD22-deﬁcient B cells.
Nevertheless, CD22 deﬁciency does affect the dynamic of a
thymus-dependent response to some degree. A recent study indi-
cates that the initial proliferative burst after a thymus-dependent
immune response is stronger if CD22 is absent. Also the formation
of germinal centers and development of plasma blasts seems to be
more rapid in the initial phase of the immune response, however
the number of antibody producing cells decreases at later time
points (Onodera et al., 2008).
Although follicular B cells in lymph nodes and spleen are not
affected in their cell numbers,mature recirculating B cells are lack-
ing in the bone marrow of CD22-deﬁcient mice (Otipoby et al.,
1996; O’Keefe et al., 1996; Sato et al., 1996; Nitschke et al., 1997).
Mice expressing CD22 with a mutated ligand binding domain dis-
play a similar phenotype (Poe et al., 2004). Notably, bone marrow
sinusoidal epithelium has been shown to express CD22 ligands
and injecting wild type mice with CD22–Fc to mask CD22 ligands
leads to a reduction of mature B cell numbers in the bone mar-
row (Nitschke et al., 1999). This suggests that CD22 interactions
with its ligands are essential for the maintenance of recirculating
B cells in the bone marrow and that CD22 might possess speciﬁc
functions as an adhesion molecule (Figure 4).
Another B cell population strongly affected by the loss of CD22
is the marginal zone B cells. Marginal zone B cells reside in close
proximity to the marginal sinus in the spleen and are believed
to play a crucial role in thymus-independent immune response
(Martin and Kearney, 2002). This population of B cells is strongly
reduced in CD22-deﬁcient mice (Samardzic et al., 2002). In agree-
ment with this ﬁnding CD22-deﬁcient mice show a reduced
immune response to thymus-independent antigen (Otipoby et al.,
1996; Nitschke et al., 1997). It has been suggested that a strong
BCR signal will favor the development of follicular B cells (and
B1 cells) while a weak signal will bias the development toward the
marginal zone B cell lineage (Pillai et al., 2004). Knock-in mice
expressing CD22 with a mutated ligand binding domain show a
similar reduction of marginal zone B cells but display weak cal-
cium signaling after anti-IgM stimulation (Poe et al., 2004). This
would indicate that the function of CD22 as an adhesive mole-
cule is crucial for placing B cells in the marginal zone. However,
knock-in mice expressing CD22 with mutated ITIM motifs show
a similar MZ B cell defect (I. Obermeier, J., Müller, M., Wöh-
ner, L., Nitschke, unpublished results). Thus it is unclear whether
direct ligand binding or modulation of signaling by CD22 deter-
mines MZ B cell numbers. It is also possible that altered survival
or proliferation of CD22-deﬁcient B cells affects different B cell
populations to a different degree and therefore mainly marginal
zone B cells are affected.
Another B cell subset involved mainly in the immune response
to thymus-independent antigens are the B1 cells. Unlike the mar-
ginal zone B cells, B1 cells seem to need a strong BCR signal for
their generation and/or maintenance. Several gene targeted mouse
lines with decreased BCR signaling show a diminished B1 cell
population. On the other hand enhanced BCR mediated signaling
due to the loss of signaling molecules known to dampen the BCR
signal or over expression of positive regulators is often associated
with increased numbers of B1a cells (Berland and Wortis, 2002).
Surprisingly, the absence of CD22 does not seem to affect B1 cell
numbers strongly. A slightly increased population of B1 cells has
been observed in two out of four independent CD22 knockout
lines generated (O’Keefe et al., 1996; Sato et al., 1998). CD22-
deﬁcient mice on a pure C57BL/6 background show normal B1
cell numbers (Nitschke et al., 1997). Although CD22 is present
on B1 cells, these results suggest that CD22 is not the dominant
inhibitor in BCR-transmitted signaling in B1 cells. In contrast,
the loss of Siglec-G is not counterbalanced by other proteins in B1
cells from Siglec-G-deﬁcient mice and thus Siglecg−/− mice show
highly increased B1 cell numbers, as well as highly increased cal-
cium mobilization in their B1 cells, when compared to wild type
B1 cells (Hoffmann et al., 2007).
Siglec-G is a direct target of the transcription factor Pax5
(Schebesta et al., 2007) and expressed throughout the B cell lin-
eage with the highest expression on B1 cells (Hoffmann et al.,
2007). Most B cell populations do not seem to be signiﬁcantly
affected by the loss of Siglec-G since Siglec-G-deﬁcient mice show
normal development of follicular and marginal zone B cells and
a largely normal immune response to thymus-dependent anti-
gen. In contrast, the population of B1 cells is highly enlarged in
Siglec-G-deﬁcient mice. B1 cells differ from conventional B cells
through their surface phenotype, localization, function, and onto-
genesis. B1 cells are the main producers of natural IgM and in
agreement with this, serum IgM levels are strongly increased in
Siglec-G-deﬁcient mice (Hoffmann et al., 2007). B1 cells can be
found in a low percentage in the spleen, but are the dominant
B cell population in the peritoneal cavity. Two distinct B1 sub-
sets have been identiﬁed in the peritoneum – the B1a (CD5+,
Mac1+, CD43+) and B1b (CD5−, Mac1+, CD43+) cells. All B1
cell subsets are found in increased numbers in Siglec-G-deﬁcient
mice with the largest expansion seen in the B1a cell population in
the peritoneal cavity. This expansion is cell intrinsic as has been
shown by adoptive transfer of mixed bone marrow cells (Hoff-
mann et al., 2007). The development of B1a cells in wild type
mice is still a matter of discussion. Most B1a cells originate from
the fetal liver and stable numbers are maintained by self-renewal.
But the adult bone marrow has not lost the capability to gener-
ate B1a cells completely. Precursor cells have been identiﬁed that
preferentially give raise to B1 cells and not to conventional B2 cells
(Montecino-Rodriguez et al., 2006). These precursors are abun-
dant in fetal liver and less frequent in adult bone marrow. However
the mechanisms leading to the development of B1 cells are proba-
blymore plastic since there is evidence that the common lymphoid
progenitor can also give rise to B1 cells (Esplin et al., 2009). As dis-
cussed, the strength of BCR signaling dramatically inﬂuences B1
cell numbers and an enhanced BCR signal leads to increased B1
cell numbers. This is consistent with the phenotype observed in
Siglec-G-deﬁcient mice. A recent study by Brenner et al. has pro-
vided the ﬁrst evidence, that the BCR signal indeed might play
a signiﬁcant role in the observed B1a cell expansion. Siglec-G-
deﬁcient mice crossed to IgM hypomorphic mice show a normal
B1a cell population. Due to the decreased levels of surface IgM
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the B1a population is nearly absent in IgM hypomorphic mice.
When crossed to Siglec-G-deﬁcient mice the effect of a low IgM
expression is probably compensated for by the loss of negative
regulation through Siglec-G and the resulting phenotype is inter-
mediate between Siglec-G-deﬁcient and IgM hypomorphic mice
leading to approximately wildtype B1 numbers (Brenner et al.,
2011).
Siglec-G-deﬁcient B1a cells show prolonged survival in vitro
and also in vivo when adoptively transferred into Rag1-deﬁcient
mice. This might lead to an accumulation of the cells and thereby
explain the enlarged population observed in Siglec-G-deﬁcient
mice. The exact biochemical pathway leading to prolonged sur-
vival of Siglec-G-deﬁcientmice is not knownbutmight include the
over expression of the transcription factor NFATc1. NFATc1 has
been suggested to play a protective role against anti-IgM induced
apoptosis in B cells. Furthermore, the loss of NFATc1 in gene tar-
geted mice speciﬁcally suppresses the development of B1 cells but
not B2 cells (Berland andWortis, 2003; Bhattacharyya et al., 2011).
Therefore it is tempting to speculate, that increased calcium signal-
ing in Siglec-G-deﬁcient mice results in higher levels of NFATc1
and subsequently in a prolonged lifespan. However, experiments
probing the contribution of increased calcium signaling to the
prolonged survival are needed to verify this hypothesis.
Another factor that may contribute to increase B1a cell num-
bers in Siglec-G-deﬁcient mice is an altered selection of B cells into
the pool of B1 cells. Fetal liver derived B1a cells show a distinct
VDJ segment usage and the repertoire of produced antibodies
is dominated by speciﬁcities for common bacterial structures
(Baumgarth et al., 2005). Analysis of the VDJ recombination in
Siglec-G-deﬁcient B1a cells and studies of the secreted antibod-
ies have shown that the BCR repertoire of Siglec-G-deﬁcient B1a
cells differs signiﬁcantly from the repertoire of wild type B1a cells
(Jellusova et al., 2010a). Similarities in the VDJ segment usage
between Siglec-G-deﬁcient B1a cells and the VDJ segment usage
reported for B cells derived from the adult bone marrow led to the
speculation that the fate decision of developing B cells is altered
in Siglec-G-deﬁcient mice and that more bone marrow-derived B
cells are selected into the B1a cell pool as in wild type mice.
Mature follicular B cells show only a mild phenotype in either
Siglec-G or CD22-deﬁcient mice. Since both Siglecs are expressed
on this population it is possible that Siglec-G andCD22might have
partly redundant functions. Indeed, Siglec-G×CD22 double-
deﬁcient mice display phenotypical features not observed in either
Siglec-G or CD22 single-deﬁcient mice. The B1 cell population
in Siglec-G×CD22 double-deﬁcient mice is enlarged, even to a
higher extent than in Siglec-G single-deﬁcient mice. Also, con-
ventional B2 cells show a pre-activated phenotype and express
higher levels of CD5, B7.2, and lower levels of CD23 (Jellusova
et al., 2010b). Surprisingly in contrast to CD22 single-deﬁcient
mice, Siglec-G×CD22 double-deﬁcient mice display an increased
population of marginal zone B cells. Serum IgM levels in Siglec-
G×CD22 double-deﬁcient mice are highly elevated and exceed
even those observed in Siglec-G single-deﬁcient mice. While
neither Siglec-G nor CD22 single-deﬁcient mice show a defect
in the immune response to thymus-dependent antigens, Siglec-
G×CD22 double-deﬁcient mice show a delayed and weaker pro-
duction of antibodies after an immunization with NP-ovalbumin.
This immunodeﬁcient phenotype is surprising since all B cell
populations (B1, follicular B, and MZ B cells) show enhanced
calcium signaling after anti-IgM stimulation. A similar phenotype
is observed in mice with a B cell speciﬁc SHP-1 deletion (Pao et al.,
2007). These mice also show an enlarged population of B1 cells,
increased BCR mediated calcium signaling in this population and
a weak immune response to thymus-dependent antigen.
CD22 AND Siglec-G LIGAND BINDING
While it is well established that a crucial function of CD22 and
Siglec-G is to inhibit B cell signaling, the important question
remains under which physiological situations the inhibitory sig-
nal is needed and how the inhibitory role of CD22 and Siglec-G
is regulated. Recent studies suggest that ligand binding might play
a crucial role. Both CD22 and Siglec-G contain an N-terminal
V-set Ig domain, which mediates binding to α2–6 linked sialic
acids (Powell et al., 1993; Engel et al., 1995; Varki and Angata,
2006). Siglec-G can additionally bind sialic acids with an α2–3
linkage (Duong et al., 2010,). Sialic acids with an α2–6 linkage
are present on different plasma proteins such as haptoglobin or
soluble IgM (Hanasaki et al., 1995; Adachi et al., 2012) and sialic
acids are also abundantly expressed on the surface of many cells.
Cells expressing sialic acid residues include T cells (Bi and Baum,
2009), cytokine activated endothelial cells (Hanasaki et al., 1994),
monocytes (Stamatos et al., 2004), erythrocytes (Aminoff et al.,
1977), and also B cells (Engel et al., 1993). Siglec-G and CD22 can
therefore engage in many different interactions and bind ligands
in trans on adjacent cell surfaces or in cis on the same cell surface.
However, probably not all possible ligand interactions are relevant
in physiological context.
The abundant expression of CD22 ligands on the cell surface of
B cells appears to “mask” most of the CD22 molecules and limits
its availability to trans ligands. Resting B cells only bind high afﬁn-
ity exogenous ligands in vitro and need to be treated with sialidase
to bind ligands of lower afﬁnity (Razi and Varki, 1998). Mask-
ing by endogenous ligands has been also shown for other Siglecs
and therefore seems to be a general property of the Siglec family
(Razi and Varki, 1999; Nakamura et al., 2002; Avril et al., 2006).
Several proteins on B cells carry Sia residues and hence could be
possible cis ligands. IgM, CD45, and CD22 itself are among the
sialylated proteins. CD22 has been shown to bind IgM and CD45
and the proximity of CD22 to the B cell receptor seems to be
crucial for its inhibitory function (Doody et al., 1995). However
this interaction does not seem to depend on sialic acid-binding
and is rather a product of protein protein interactions (Zhang and
Varki, 2004). Instead CD22 itself seems to be the prominent cis
ligand and CD22 homomultimers can be found on resting B cells
(Figure 3; Han et al., 2005).
Even though the availability of CD22 for trans interactions on
resting mature B cells seems to be very limited, there are some
speciﬁc B cell populations with constantly unmasked CD22. A
small part of freshly isolated splenic cells can be stained with a
streptavidin-based sialylated artiﬁcial CD22 ligand without siali-
dase pretreatment. The frequency of B cells with unmasked CD22
is higher in marginal zone B cells, transitional B cells, and peri-
toneal B1a compared tomature splenic B cells (Danzer et al., 2003).
B cells with unmasked CD22 are also enriched in the bone marrow
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FIGURE 3 | Model of CD22 cis interactions. Several proteins on the B cell
surface are sialylated, however a large part of the CD22 molecules seems to
interact via sialic acid-binding mainly with other CD22 molecules [shown in
(A)]. The formation of homomultimers is disrupted in B cells from mice
expressing CD22 that cannot bind sialic acids. This makes CD22 more
available to interactions with the BCR and subsequently leads to a stronger
inhibition of the BCR signal [shown in (B)]. A similar situation might arise in
ST6Gal-deﬁcient mice lacking CD22 ligands.
(Floyd et al., 2000). It is tempting to speculate that unmaskedCD22
indicates an activated state of these B cells, since unmasked murine
splenic B cells have been shown to express higher levels of the acti-
vation markers CD69, MHCII, and B7.2 (Danzer et al., 2003) and
in subpopulations of human B cells CD22 becomes unmasked
after anti-IgM and CD40 stimulation (Razi and Varki, 1998).
To study whether ligand binding contributes to the inhibitory
function of CD22 on BCR mediated signaling CD22 mutant mice
were generated that either completely lack the ligand binding
domain or harbor mutations in R130 and R137 which are critical
amino acids for CD22–sialic acid interactions (Poe et al., 2004).
Studies using these knock-in mice have shown that Sia binding
modiﬁes CD22 activity, however in a – at the ﬁrst sight – unex-
pected way. It has been shown that simultaneous engagement of
CD22 and the BCR with a sialylated antigen effectively inhibits the
BCR signal (Courtney et al., 2009). This might happen in a natural
environment when antigens binding to the BCR contain also sialy-
lated structures and are therefore recognized by CD22. Therefore,
the ability of CD22 to bind sialic acids appears to be crucial for
its inhibitory function. This has been at ﬁrst conﬁrmed by stud-
ies using cell lines from Cd22−/− mice transfected with CD22
mutants. These cell lines with CD22 mutants lacking the sia bind-
ing domain or with R130A and R137E point mutations showed
increased calcium signaling after anti-IgM stimulation (Jin et al.,
2002). Also, treatment of B cell lines with high afﬁnity artiﬁcial
CD22 ligands led to increased BCR-induced Ca2+ (Kelm et al.,
2002). Surprisingly, these ﬁndings could not be conﬁrmed in gene
targeted mice carrying similar mutations. Freshly isolated splenic
B cells from CD22 mutant mice with disrupted ligand binding
showed a normal or even a lower calcium signal after anti-IgM
stimulation than wildtype mice (Poe et al., 2004; I. Obermeier,
J., Müller, M., Wöhner, L., Nitschke, unpublished results). Several
models explaining this ﬁnding have been proposed but none of
them can unify the results obtained from cell lines and mouse
primary B cells. The current model holds that in unstimulated B
cells, CD22 forms homomultimers and is not associated with the
BCR. Through photoafﬁnity crosslinking Han et al. (2005) have
shown that even though multiple proteins on the B cell surface
are sialylated and can be bound by CD22–Fc molecules in vitro,
CD22 binds sialic acids only on other CD22 molecules in situ. Dis-
rupting 2,6 Sia-binding and therefore the formation of multimers
might free CD22 and change the distribution of the molecules so
that more of them are now available for interactions with the BCR
(Figure 3.) This would explain why the calcium signal is normal
or decreased in B cells from CD22 knock-in mice with disrupted
ligand binding. However, it is also possible that our understanding
of the biological changes in these B cells is not complete since they
show a pre-activated phenotype with lower levels of surface IgM
and the responsiveness to anti-IgM might be affected also by other
factors.
In addition to cis-binding, CD22 has also been suggested to
engage in B cell–T cell or B cell–B cell interactions. B cell acti-
vation by antigen displayed on the surface of a target cell can be
suppressed when the target cell co-expresses a 2,6 linked sialic
acids. This interaction with target cells which co-express antigen
and 2,6 Sia may induce co-ligation of CD22 and the BCR, lead-
ing to enhanced CD22-mediated inhibition (Lanoue et al., 2002;
Figure 4.) In homotypic interactions, CD22 colocalizes with the
BCR in clustered B cells at the site of contact and is believed to bind
IgM on opposing B cells (Ramya et al., 2010). B cells deﬁcient in
ST6Gal, an enzyme creating CD22 ligands, show an equal CD22
distribution on the cell surface, however if in contact with wild
type cells distribution to the site of contact is restored. In contrast,
wild typeB cells fail to do sowhen in contactwith ST6Gal-deﬁcient
B cells showing that it is the ligand on the neighboring cell that
recruits CD22 to the site of contact (Collins et al., 2004). This indi-
cates that ligand binding by CD22 is a dynamic process and even
though CD22 molecules appear to be masked on resting B cells
they are not completely unavailable to trans interactions. Another
CD22 trans ligand could be CD45 and CD22 has been reported
to recognize CD45 on T cells (Sgroi et al., 1995). However the
physiological relevance of CD22-mediated T cell–B cell and B
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FIGURE 4 | Possible roles for CD22 trans interactions. CD22 can bind
ligands on neighboring cells and also on soluble proteins and thereby
inﬂuence different biological processes. (A)Through binding of α2,6 sialic
acids on sinusoidal endothelium, CD22 is believed to play a crucial role in the
retention or homing of mature B cells to the bone marrow. (B) CD22 can
participate in cell –cell interactions by binding to sialylated ligands on the
opposing cell. Increased colocalization of CD22 and BCR molecules could
lead to a stronger CD22-mediated inhibition. (C) Antigens engaging the BCR
(yellow symbols), but also containing sialic acids (red circles) recruit CD22 to
the BCR. This leads to a stronger inhibition of the BCR signal and might be
one of the mechanisms how tolerance to self-antigens containing CD22
ligands is maintained.
cell–B cell interactions remains elusive. As already mentioned, the
sinusoidal endothelium of the bone marrow also contains CD22
ligands and these ligands seem to be important for the reten-
tion of mature recirculating B cells (Nitschke et al., 1999). It is
possible that the role of CD22 as an adhesion molecule is inde-
pendent of its role as a signaling molecule in the BCR cascade
and therefore studies addressing these functions in separate mod-
els are needed. The interaction of CD22 with cells might be even
more complex and exceed α2,6 Sia mediated binding. One study
reports cell contact dependent but sia independent inhibition of
B cell proliferation by bone marrow dendritic cells (Santos et al.,
2008).
Apart from interactions with proteins expressed on the cell sur-
face, CD22 can also bind secreted proteins. Soluble immunoglob-
ulins can contain sialylated epitopes and can be recognized by
CD22 under certain conditions. Treatment of NP-speciﬁc B cells
with NP ligated to IgM, simulating an antigen–antibody com-
plex, resulted in higher calcium if sialylation of the complex was
removed by neuraminidase treatment. Relative inhibition of the
calcium signal depending on the sialylation status of the complex
was not observed in CD22-deﬁcient control B cells. Thus the sialy-
lated residues linked to serum IgM might serve as a trans ligand for
CD22 and trigger an inhibitory signal if the BCR is simultaneously
activated (Adachi et al., 2012).
During an immune response B cells are induced to switch to
produce antibodies of the IgG isotype. IgG antibodies can mediate
pro-inﬂammatory but also anti-inﬂammatory functions resulting
fromdifferential sialylation of the Fc domain (Kaneko et al., 2006).
An example formedical use of the anti-inﬂammatory properties of
IgG is intravenous immunoglobulin (IVIG). IVIG consists mostly
of human polyspeciﬁc IgG prepared from the plasma of several
thousand donors. It is widely used to treat humans suffering
from different autoimmune diseases including systemic lupus ery-
thematosus (SLE). The exact mechanism how IVIG inﬂuences
immune functions is still not clearly deﬁnedbutmaybe a combina-
tion of several different processes. IVIG has been shown to reduce
the viability of tonsilar B cells. Binding of IVIG was shown to
modulate signaling after anti-IgM stimulation leading to cell cycle
arrest and apoptosis of the cells. The effects of IVIG co-treatment
included increased CD22 phosphorylation and decreased phos-
phorylation of CD19 and BLNK/SLP65 (Seite et al., 2010). These
effects were only observed with the fraction enriched in sialylated
immunoglobulins but not with the fraction free of sialic acid. Fur-
thermore, IVIG was shown to colocalize with CD22 on the B cell
surface and this colocalization was dependent on the presence of
sialic acid. It is therefore possible that IVIG can modulate B cell
functions by binding to CD22, which might lead to inhibition of
cell cycle progression and result in apoptosis of the cells (Seite
et al., 2010).
SIALYLTRANSFERASES INVOLVED IN THE SYNTHESIS OF
CD22 LIGANDS
Since binding of ligands seems to be important for several CD22-
mediated functions, further insight into the role of CD22 can
be gained by studying mice deﬁcient in speciﬁc enzymes creat-
ing these sugar structures. Sialic acids are attached to glycans via
α2,3, α2,6, and α2,8 linkages and these glycan modiﬁcations are
mediated by distinct enzymes. Four types of β-galactoside α2,3
sialyltransferases (ST3Gal) have been identiﬁed in mice and α2,3
linked sialic acids can be found on a great variety of cells (Kono
et al., 1997). Alpha 2,6 linked sialic acids are less common and can
be generated by several different enzymes (Takashima, 2008).
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CD22 requires α2,6 linked sialic acid to galactose as a ligand
and the ST6Gal I sialyltransferase is unique in its function of pro-
ducing these ligands (Collins et al., 2002) and has been found to
be expressed in hematopoietic cells and liver.
ST6GalI-deﬁcient mice lack CD22 ligands and phenocopy
CD22 knock-in mice with a mutated ligand binding domain in
several ways. Isolated splenic B cells show lower calcium mobiliza-
tion after IgM engagement than wildtype cells, the expression of
CD22 and IgM on the cell surface is reduced and the B cells show
suboptimal BCR-induced proliferation (Hennet et al., 1998; Poe
et al., 2004). Since ST6GalI-deﬁcient mice display a global change
in sialylation and therefore other proteinsmight be affected in their
function, one could argue that decreased calcium signaling could
be a byproduct of these alterations and not dependent on CD22.
However St6GalI×CD22 double-deﬁcient mice show a calcium
ﬂux comparable with CD22-deﬁcient mice. This indicates that the
loss of CD22 function is dominant and affects the signal even
in ST6GalI-deﬁcient B cells (Collins et al., 2006b; Ghosh et al.,
2006). It is tempting to speculate that decreased calcium signaling
in St6GalI-deﬁcient B cells as well as in CD22 knock-in cells is
a product of an enhanced CD22 signal rather than a diminished.
ST6GalI-deﬁcient B cells show increased association of CD22 with
the BCR (Collins et al., 2006b) and a stronger IgM induced CD22
phosphorylation.
B cell development in ST6GalI-deﬁcient mice is normal, but
the population of recirculating mature B cells in the bone marrow
and the marginal zone B cells in the spleen are reduced (Collins
et al., 2006b; Ghosh et al., 2006). This is in agreement with the
phenotype observed in CD22 knock-in and CD22-deﬁcient mice
and supports themodel, that CD22–Sia interactions are important
for those two B cell subsets. Unlike CD22-deﬁcient mice, ST6GalI-
deﬁcient mice show severely impaired immune responses to both
thymus-independent and thymus-dependent antigens (Hennet
et al., 1998). The exact mechanism leading to this phenotype is
not clariﬁed yet. It is possible that the stronger inhibition by CD22
renders the B cells irresponsive to activation. However, it is inter-
esting that Siglec-G×CD22 double-deﬁcient mice also respond
only weakly to both thymus-dependent and thymus-independent
immunization even though they show a very strong calcium sig-
nal after anti-IgM stimulation (Jellusova et al., 2010b). Siglec-G
binds α2,6 Sia ligands, as well as a2,3 Sia ligands, and therefore a
substantial part of its ligands might be missing in St6gal−/− mice.
Another enzyme associated with the generation of CD22 lig-
ands is CMP-Neu5Ac hydroxylase (Cmah). In mice, Sia can be
found in two main forms – Neu5Ac and Neu5Gc. Both forms
differ only in one oxygen molecule added to C5 to form Neu5Gc.
The enzymeCmah is responsible for thismodiﬁcation and changes
Neu5Ac toNeu5Gc.Humans lost the enzymeduring evolution and
therefore express exclusively Neu5Ac (Varki, 2009). While human
CD22 can bind both forms of sialic acids, murine CD22 shows
preferential binding to Neu5Gc. Splenic cells from Cmah-deﬁcient
mice show substantially weaker binding of a chimeric mCD22–Fc
protein (a fusion protein consisting of the N-terminal domain of
mouse CD22 and the Fc region of human IgG1) than wildtype
cells, demonstrating strong reduction of CD22 ligands in these
cells (Naito et al., 2007). Interestingly, the rat monoclonal anti-
body GL7 has been found to speciﬁcally bind the Neu5Ac sialic
acid form linked to the sugar backbone in an α2,6 linkage. GL7 is
widely used to identify germinal center B cells.Also LPS activatedB
cells and some B cells in the bone marrow can be stained with GL7
(Cervenak et al., 2001). This indicates that the expression of CD22
ligands changes with the activation status of B cells. Indeed the
expression of Cmah is strongly reduced in germinal center B cells
and mCD22–Fc binding is diminished (Naito et al., 2007). Most
in vitro experiments performed to study the biochemical path-
ways inﬂuenced by CD22 have been conducted with naïve splenic
B cells. It could be interesting to extend these studies to germinal
center B cells, since the lack of CD22 ligands indicates that inter-
action between CD22 and other proteins might be different in this
speciﬁc B cell population.
Cmah-deﬁcient mice show a subtle phenotype reminiscent
of CD22-deﬁcient mice rather than St6Gal-deﬁcient mice. The
immune response to a thymus-independent antigen is increased,
and normal to thymus-dependent antigen. Calcium signaling after
anti-IgM stimulation is enhanced and the marginal zone and
recirculating B cell populations are decreased (Naito et al., 2007).
Another common sialic acid modiﬁcation is O-acetylation on
the C9 position. In vitro studies have shown that CD22 binding
to acetylated sialic acids on the C9 position is impaired (Sjoberg
et al., 1994). The enzyme Sialate: O-acetyl esterase (Siae) is capa-
ble of removing acetyl groups from the 9-OH position of α2,6
sialic acids. This enzyme is upregulated in mature B cells, suggest-
ing a role in B cell biology. The phenotype of Siae-deﬁcient mice
is again similar to the phenotype of CD22-deﬁcient mice. Cal-
cium signaling after BCR stimulation is elevated, the populations
of marginal zone and recirculating B cells are decreased in their
numbers (Cariappa et al., 2009).
REGULATION OF CD22 SURFACE EXPRESSION AND
ENDOCYTOSIS
CD22 functionality can be regulated by cis-ligandbinding of CD22
which affects association to the BCR, but also the expression lev-
els of CD22 on the cell surface can be modulated. CD22 surface
expression on conventional B2 cells is decreased after IgM liga-
tion, but increased after LPS or anti-CD40 stimulation. The down
regulation of surface CD22 after BCR crosslinking is probably a
result of the decreased CD22 mRNA levels observed after 24 h of
cell culture (Lajaunias et al., 2002). Furthermore, CD22 expres-
sion on the cell surface can be regulated by modulating CD22
internalization. CD22 can be recruited to clathrin-rich domains
and internalized after stimulation with monoclonal antibodies or
high afﬁnity sialosides (Chan et al., 1998; Collins et al., 2006a).
CD22 has been shown to interact with the adapter protein AP50,
a subunit of the AP-2 complex. This complex is known to mediate
recruitment of different receptors into clathrin coated pits. CD22
is believed to interact with AP50 via its tyrosine motifs and the
removal of the cytoplasmic tail abolishes CD22 endocytosis. Also,
while the treatment of B cells with monoclonal anti-CD22 anti-
bodies promotes the internalization of CD22, BCR stimulation
and subsequent CD22 phosphorylation transiently inhibit CD22
endocytosis (John et al., 2003). After internalization CD22 is able
to release bound ligands and recycle back to the cell surface. In
contrast, monoclonal antibodies bound to CD22 are believed to
recycle togetherwithCD22 to the cell surface (O’Reilly et al., 2011).
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This ﬁnding is important when constructs are designed to target
CD22 in B cell lymphomas.
ROLE OF CD22 IN B CELL PROLIFERATION AND APOPTOSIS
B cell antigen receptor mediated signaling can lead to apopto-
sis or proliferation depending on the developmental status of B
cells and other costimulatory or inhibitory signals. Equally, the
impact of CD22 signaling on B cell proliferation and apoptosis
varies depending on the context of other signals. CD22-deﬁcient
B cells show decreased proliferation to anti-IgM stimulation, but
normal or increased proliferation to TLR or CD40 stimulation
(Nitschke et al., 1997). The observed differences could be a conse-
quence of a missing CD22 signal and might show a direct role
of CD22 signaling in these signaling pathways. However, it is
also possible that altered proliferative responses are an indirect
product of CD22 deﬁciency, since CD22-deﬁcient B cells show
a pre-activated phenotype. Nevertheless, CD22 crosslinking with
monoclonal antibodies can change the proliferative and survival
properties of B cells depending on additional signals provided,
the type of B cells and even the type of the chosen antibody.
Antibodies blocking the ligand binding domain of human CD22
such as the monoclonal antibody HB22.7 have been shown to
induce apoptosis in B cell lymphoma cell lines (Tuscano et al.,
1999). This effect is not seen with antibodies targeting other parts
of the CD22 molecule. However, how this stimulation relates to
physiological functions of CD22 is unclear. Interestingly, mutated
CD22 lacking a large part of the cytoplasmic tail was found in
infants diagnosed with B-precursor leukemia (Uckun et al., 2010).
Leukemic cells expressing CD22 in this truncated form were resis-
tant to apoptosis induction by the HB22.7 monoclonal antibody
and caused leukemia when injected into SCID mice. Transgenic
mice expressing human CD22 with deleted exon 12 developed B
cell hyperplasia. This suggests that dysregulated CD22 signaling
can have proliferation-promoting effects on B cells (Uckun et al.,
2010).
THE ROLE OF CD22 AND Siglec-G IN TOLERANCE AND
AUTOIMMUNITY
B cell activation needs to be tightly regulated to avoid autoim-
munity while maintaining an adequate immune response to
pathogens. Hyperresponsiveness of B cells due to defective inhi-
bition of the BCR signal often results in the development of
autoimmunity.
Mice lacking the inhibitory receptor FcγRIIb on a C57BL/6
background develop anti-nuclear autoantibodies leading to
glomerulonephritis and increasedmortality (Bolland andRavetch,
2000).Alsomicedeﬁcient in cytosolic signalingmolecules involved
in negative signaling pathways such as SHP-1 and Lyn (Chan
et al., 1997) show signs of autoimmunity as well. Both CD22 and
Siglec-G are negative regulators of the BCR signal, therefore it
was expected that the loss of either of these proteins would predis-
pose to autoimmunity. Several studies have linkedCD22deﬁciency
to the development of autoimmunity. In one out of four sepa-
rately generated Cd22−/− lines autoantibodies could be detected
in aging mice (O’Keefe et al., 1999). When CD22-deﬁcient mice
were crossed toY linked autoimmune accelerator (YAA) mice even
heterozygositywould lead to the production of IgG autoantibodies
(Mary et al., 2000). However, caution is needed when interpreting
these results. These studies have been performed using a CD22
line generated with the aid of 129 embryonic stem cells and subse-
quently crossed to the C57BL/6 background. It has recently been
shown that several 129-derived loci contribute to the development
of autoimmunity on a C57/BL6 background (Bygrave et al., 2004;
Heidari et al., 2006). CD22 is known to be in close proximity to
one of those loci on the murine chromosome 7. Since this locus
is linked to the CD22 locus they might be inherited together in
CD22-deﬁcient mice. In contrast, this locus might be lost in the
process of backcrossing in wild type controls since the gene for
wild type CD22 will be derived from the C57BL/6 background.
Therefore mice generated with this breeding strategy might show
a higher production of autoantibodies in CD22-deﬁcient animals
compared to the control animals irrespective of the CD22 deﬁ-
ciency. Indeed, mice generated with C57BL/6 embryonic stem
cells do not show any signs of autoimmunity. Therefore the loss of
CD22 alone does not seem to be enough for spontaneous develop-
ment of autoantibodies. However,CD22 deﬁciency might increase
the susceptibility to autoimmunedisorders on abackgroundwhere
other factors predispose to autoimmunity. Notable, several mouse
strains prone to develop autoimmunity such as NZW, MRL, and
BXSB carry different CD22 alleles compared to the mouse strains
C57BL/6 and BALB/c (Lajaunias et al., 1999; Mary et al., 2000).
The Cd22a allele and the related Cd22c allele associated with lupus
prone genetic backgrounds lead to the expression of aberrant
CD22 proteins. The truncated CD22 protein in Cd22a strains is
constitutively unmasked and is possibly impaired in its ability to
bind natural ligands. Alternative splicing of the Cd22a mRNA can
lead to deletions in the ligand binding domain (Mary et al., 2000).
To assess the functional effect of the aberrant Cd22a allele on a
normal genetic background B6.CD22 congenic mice have been
generated. B cells from these mice show a similar phenotype to
CD22 knock-in mice with a mutated ligand binding domain. They
show decreased surface IgM expression and increased expression
of MHCII. Calcium signaling after anti-IgM stimulation seems to
be normal (Nitschke et al., 2006).
Siglec-G-deﬁcient mice show an increased population of B1a
cells and elevated serum IgM levels. Multiple autoimmune-prone
mouse strains (e.g., NZB/W, NZB) have enlarged populations of
B1 cells. Also in several gene targeted mice autoimmunity cor-
relates with increased B1 cell numbers. Although controversially
discussed, B1 cells might play a direct role in the development of
autoimmunity. The BCR repertoire of B1 cells is skewed toward
polyreactive,weakly auto-reactive antibodies. These antibodies are
usually of the IgM isotype and not pathogenic under normal con-
ditions. However dysregulated B cell signaling could possibly lead
to isotype switching and to the development of high afﬁnity IgG
autoantibodies. Also, B1 cells might contribute to the develop-
ment of autoimmune pathologies through antigen presentation or
secretion of cytokines (Duan and Morel, 2006). However Siglec-
G-deﬁcient mice do not develop high afﬁnity IgG autoantibodies
and also no signs of renal dysfunction are observed. The only
potentially pathogenic autoantibodies found in aged Siglec-G-
deﬁcient mice are Rhesus factor IgM and anti-erythrocyte IgM
(Hoffmann et al., 2007). However no differences in survival or
general well-being have been observed between wild type and
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Siglec-G-deﬁcient mice. Both types of autoantibodies found are
of the IgM isotype and probably reﬂect the overall increased levels
of serum IgM. This demonstrates that an enlarged B1a cell popu-
lation and hyperactive B1 cells are not sufﬁcient to spontaneously
develop autoimmunity.
Neither Siglec-G deﬁciency nor CD22 ablation alone seem to
result in spontaneous production of autoantibodies. However,
as already mentioned Siglec-G and CD22 seem to have partly
redundant functions. It is therefore possible that the expression
of either one of those receptors is sufﬁcient to maintain toler-
ance and only the ablation of both molecules would have a more
profound effect. Indeed, Siglec-G ×CD22 double-deﬁcient mice
develop signiﬁcant levels of IgG autoantibodies with speciﬁci-
ties including ssDNA, dsDNA, and RNA (Jellusova et al., 2010b).
In some of these mice deposition of antibodies in the kidneys
couldbedetected,accompaniedbymild glomerular nephritis. Fur-
thermore, Siglecg−/− Cd22+/− and Siglecg+/− Cd22−/− mice
also developed autoantibodies although at later time points than
Siglec-G×CD22 double-deﬁcient mice (Jellusova et al., 2010b).
This suggests that Siglec-G and CD22 are essential for the mainte-
nance of tolerance and also that a possible gene dosage effect could
take place since mice with three mutated alleles show develop-
ment of autoantibodies unlike Siglec-G or CD22 single-deﬁcient
mice. An interesting model explaining how Siglec-G and CD22
contribute to the maintenance of tolerance postulates that anti-
gen containing sialylated epitopes in trans will bring Siglec-G and
CD22 in close proximity to the BCR and therefore inhibit the
immune response. Since sialic acids are abundant in vertebrates,
but less frequent in bacteria, sialylated structures might therefore
provide a suitable signal to distinguish between self-antigen and
foreign structures (Figure 4; Duong et al., 2010).
There is no convincing link between CD22 polymorphisms
in humans and autoimmune diseases. Genome-wide association
studies have not detected human CD22 or SIGLEC10 as suscep-
tibility loci, e.g., in SLE (Criswell, 2008). However, functionally
defective rare variants in the human SIAE gene have been detected
as being associated with several human autoimmune diseases
(Surolia et al., 2010). A similar phenotype was observed in SIAE-
deﬁcient mice. This ﬁnding is relevant to Siglec biology, as the
enzyme SIAE modiﬁes CD22- and Siglec-G-ligands on B cells,
thus affects the same pathway.
CONCLUSION
Siglec-G andCD22 are twomembers of the Siglec family expressed
onBcells. They share the ability to bind sialic acids and inhibit BCR
mediated signaling. They might possess some redundant function
as shown with the aid of Siglec-G×CD22 double-deﬁcient mice.
The loss of both proteins results in an activated B cell phenotype,
increased calcium signaling after anti-IgM stimulation, a weaker
immune response and spontaneous production of autoantibod-
ies. Interestingly, Siglec-G and CD22 also play unique roles on
speciﬁc B cell populations and the loss of either receptor is not
functionally compensated through the other in these cells. CD22
seems to play a crucial role in marginal zone B cells in the spleen
and mature recirculating B cells in the bone marrow since both
B cell populations are diminished in CD22-deﬁcient mice. CD22
seems to be also the dominant inhibitor of calcium signaling in
conventional B2 cells. Siglec-G on the other hand is crucial for the
inhibition of BCR mediated signaling in B1 cells and also regulates
their survival and antibody repertoire. An interesting aspect of the
Siglec function is their ability to bind sialic acids and to couple
the signal to their regulatory role of the BCR-transmitted signal.
Some valuable insight has been already gained in the biological
function of ligand binding through CD22, however certain issues
still remain unresolved. The role of Siglec-G ligand binding is not
characterized yet and would be interesting to study in future.
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